MiLaboratories
@milaboratories.bsky.social
Creators of MiXCR & Platforma: the leading software for the analysis of NGS data for immune profiling. Posting updates on software releases and new features.
Platforma.bio
Platforma.bio
What a year for our global research community 🌍
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
December 18, 2025 at 11:24 AM
What a year for our global research community 🌍
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
In 2025, together we:
• Processed 1.5 PB of data (+50% YoY)
• Welcomed 2,400 new users across 375 institutions
• Were cited in 741 publications
• Shipped 30 new biological blocks
On to an even bigger 2026 🚀
What if we’ve been studying TILs wrong?
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
December 15, 2025 at 5:36 PM
What if we’ve been studying TILs wrong?
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
A new low-intervention study found:
— High-TIL areas had both CD4+ and CD8+ T cells
— Low-TIL areas skewed to CD4+ T cells with fewer cytotoxic markers
— CD4+ T cells had less diverse TCRs
MiXCR identified TILs with the highest therapeutic potential.
Antibody discovery becomes far more powerful when functional assay data and NGS are brought together.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
December 10, 2025 at 1:59 PM
Antibody discovery becomes far more powerful when functional assay data and NGS are brought together.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
In Platforma’s antibody space, overlaying immune assay targets with clonotypes makes enriched, functionally validated clones pop instantly, letting teams spot high-value hits faster.
Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse.
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
December 9, 2025 at 4:13 PM
Coupled with other filters for sequence liability and enrichment scores, this decision funnel guarantees a panel of leads that are both enriched and biologically diverse.
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Couldn't make it to our webinar? Watch the recording on-demand:
www.youtube.com/watch?v=hhsL...
Last week during our antibody discovery webinar, we gave a live demo of our lead selection block.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
December 9, 2025 at 4:12 PM
Last week during our antibody discovery webinar, we gave a live demo of our lead selection block.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Unlike the common “Top N” approach, which can bias selection toward a single dominant family, we use a Diversity-First algorithm to pick the top representative from each family to ensure diversity.
Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET!
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
https://bit.ly/4oVepwJ
t.co
December 2, 2025 at 7:03 AM
Last chance to register for our antibody discovery webinar tomorrow at 11 AM EST/ 5 PM CET!
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Learn how to:
• Uncover emergent clones & immune responses
• Track enrichment and liabilities
• Predict structure & affinity from sequence
• Find top leads without coding
Sign up here: t.co/3Ye6fj1EAA
Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
November 27, 2025 at 4:26 PM
Wrapping up our last Platforma Pioneers workshop at @bostonchildrens.bsky.social!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Joining forces with over 40 members of the Harvard network, our team helped spark collaboration and share knowledge, empowering biologists to run their own downstream analyses themselves.
Thank you for hosting us!
Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates?
Join our webinar next week.
bit.ly/4oY9s69
Join our webinar next week.
bit.ly/4oY9s69
November 25, 2025 at 1:24 PM
Want to learn more about how top teams combine sequence, functional, and structural analysis to prioritize true therapeutic candidates?
Join our webinar next week.
bit.ly/4oY9s69
Join our webinar next week.
bit.ly/4oY9s69
What everyone in antibody discovery should know:
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
November 25, 2025 at 1:24 PM
What everyone in antibody discovery should know:
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
1. How to combine NGS with functional assay data to reveal truly high-potential clones
2. Not all lead candidates are therapeutic candidates
3. Prioritize developability from the start. Spot sequence liabilities early to derisk your pipeline.
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
November 20, 2025 at 12:23 PM
MiXCR powered BCR extraction in this study, and with Platforma you can now go further—model structure, predict binding affinity, and rank top antibody leads by developability.
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
Learn more here: platforma.bio/antibody-dis...
#antibody #antibodydiscovery #antibodyengineering
🧬 New deep learning model profiles antigen–antibody interactions at scale!
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
November 20, 2025 at 12:21 PM
🧬 New deep learning model profiles antigen–antibody interactions at scale!
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Cmai predicts antigen–BCR binding from standard RNA-seq with >0.90 AUROC—unlocking biomarker discovery, treatment response prediction, and even forecasting immune-related toxicities up to 120 days before onset.
Platforma Pioneers Tour — UCSD & @lji.org
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
November 19, 2025 at 12:40 PM
Platforma Pioneers Tour — UCSD & @lji.org
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
40 researchers, one clear takeaway: Platforma bridges the gap.
Biologists can analyze data without waiting
Core facilities empower users beyond count matrices
Bioinformaticians can focus on innovation
Platforma doesn't replace expertise, it unlocks it.
Want to accelerate your antibody discovery workflow?
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
November 13, 2025 at 3:36 PM
Want to accelerate your antibody discovery workflow?
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
Join our webinar to learn how to prioritize lead candidates faster.
You’ll discover how to track enrichment and liabilities, monitor clone dynamics over time, and predict developability to minimize risk
Register here: bit.ly/4p8157W
This week, we kicked off our Platforma Pioneers academic tour at UCLA!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
November 12, 2025 at 2:46 PM
This week, we kicked off our Platforma Pioneers academic tour at UCLA!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
Our hands-on workshop on how to accelerate no-code NGS data analysis with Platforma was a blast.
A big thank you to everyone who joined us—we loved seeing your curiosity and creativity in action!
🚗 Next stops - USC and UCSD!
RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma?
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
November 6, 2025 at 12:42 PM
RNA-seq to monitor minimal residual disease (MRD) in multiple myeloma?
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
A recent Nature study found that RNA-seq achieved higher sensitivity and stronger prognostic value than DNA-seq for MRD.
We're proud that MiXCR was the key tool in this study.
Read more here: x.com/MiLaboratori...
We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building.
Thanks to everyone who stopped by!
Thanks to everyone who stopped by!
November 5, 2025 at 2:50 PM
We just wrapped up two impactful days at the Cell Symposium in Sitges, Spain with Cellecta! Was great to be face-to-face with researchers: live demos of Platforma, learning more about what others are working on, and sharing what our teams have been building.
Thanks to everyone who stopped by!
Thanks to everyone who stopped by!
Proud to share a new study advancing non-invasive immune monitoring in cancer. Researchers found tumor-derived TCR clonotypes enriched in cfDNA and persisting >50 weeks in circulating T cells.
Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA.
#cfDNA #TCRseq #TCR
Proud that MiXCR powered large-scale TCR sequencing across tumor, blood, and cfDNA.
#cfDNA #TCRseq #TCR
October 30, 2025 at 11:44 AM
Big news: we’ve launched an interactive demo on the Platforma website!
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
October 28, 2025 at 8:06 AM
Big news: we’ve launched an interactive demo on the Platforma website!
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
Choose your own scientific adventure:
🔹 Antibody Discovery
🔹 Differential Gene Expression
🔹 Single Cell Multiomics
🔹 TCR/BCR Repertoire Analysis
👉 Dive into the demo here: shorturl.at/7tkD4
#NGS #Multiomics #TCR #BCR
🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao!
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
MiLaboratories hiring Scientific Sales Development Representative in Bilbao, Basque Country, Spain | LinkedIn
Posted 11:04:05 AM. TL;DR🧬 NGS data analysis platform for biologists🚀 Backed by Speedinvest and K Fund among others —…See this and similar jobs on LinkedIn.
lnkd.in
October 27, 2025 at 6:45 PM
🧬 Join our team: We’re hiring a Scientific Sales Development Representative in Bilbao!
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
Who you are: Degree in Biology/Bioinformatics (or similar), strong English, 0–2 years’ experience
lnkd.in/dxMXRT84
🔬 Empowering the next generation of scientists!
Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets.
Thanks to everyone who joined!
#bioinformatics #NGS
Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets.
Thanks to everyone who joined!
#bioinformatics #NGS
October 23, 2025 at 1:18 PM
🔬 Empowering the next generation of scientists!
Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets.
Thanks to everyone who joined!
#bioinformatics #NGS
Today, our team hosted a hands-on Platforma workshop at the University of Navarra, where researchers explored Platforma's powerful functionalities hands on with real datasets.
Thanks to everyone who joined!
#bioinformatics #NGS
🔬 Transform your B-cell research with Platforma - no coding required:
✔️ Annotate & build clonotypes with quality controls
✔️ Run clonality analyses across studies & patient groups
✔️ Cluster B cells, perform differential analysis, & explore UMAP
bit.ly/42QDhNb
Download today: platforma.bio
✔️ Annotate & build clonotypes with quality controls
✔️ Run clonality analyses across studies & patient groups
✔️ Cluster B cells, perform differential analysis, & explore UMAP
bit.ly/42QDhNb
Download today: platforma.bio
BCR Repertoire Analysis | Antibody Clonotypes & Diversity with Platforma
YouTube video by MiLaboratories
www.youtube.com
October 22, 2025 at 9:52 AM
🔬 Transform your B-cell research with Platforma - no coding required:
✔️ Annotate & build clonotypes with quality controls
✔️ Run clonality analyses across studies & patient groups
✔️ Cluster B cells, perform differential analysis, & explore UMAP
bit.ly/42QDhNb
Download today: platforma.bio
✔️ Annotate & build clonotypes with quality controls
✔️ Run clonality analyses across studies & patient groups
✔️ Cluster B cells, perform differential analysis, & explore UMAP
bit.ly/42QDhNb
Download today: platforma.bio
Although we couldn’t make it to #ASHG2025, our partner Illumina presented a fantastic study on accurate full-length V(D)J clonotype detection using high-quality long reads on the MiSeq™ i100.
We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.
We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.
October 17, 2025 at 8:36 AM
Although we couldn’t make it to #ASHG2025, our partner Illumina presented a fantastic study on accurate full-length V(D)J clonotype detection using high-quality long reads on the MiSeq™ i100.
We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.
We’re especially proud that MiXCR was used to enable precise immune repertoire profiling.
A major leap forward in treatment for Addison’s Disease!
In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model.
We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.
In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model.
We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.
October 16, 2025 at 11:12 AM
A major leap forward in treatment for Addison’s Disease!
In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model.
We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.
In a new publication from bioRxiv, researchers pinpointed IFN-γ–producing self-reactive CD4+ T cells as the main drivers of autoimmune adrenalitis in a mouse model.
We're proud that MiXCR enabled analysis of TCR clonotypes from scRNAseq.
Gene expression analysis with bulk RNA-seq data traditionally involves many steps (preprocessing, differential expression, pathway enrichment) + bioinformatics expertise
Platforma changes that.
Watch how we perform gene expression analysis in just a few clicks.
www.youtube.com/watch?v=K7aq...
Platforma changes that.
Watch how we perform gene expression analysis in just a few clicks.
www.youtube.com/watch?v=K7aq...
Differential Gene Expression Analysis | Bulk RNA-seq Pipeline in Platforma
YouTube video by MiLaboratories
www.youtube.com
October 15, 2025 at 11:56 AM
Gene expression analysis with bulk RNA-seq data traditionally involves many steps (preprocessing, differential expression, pathway enrichment) + bioinformatics expertise
Platforma changes that.
Watch how we perform gene expression analysis in just a few clicks.
www.youtube.com/watch?v=K7aq...
Platforma changes that.
Watch how we perform gene expression analysis in just a few clicks.
www.youtube.com/watch?v=K7aq...
New Case Study featuring MiXCR + Qiagen: University of Antwerp pioneers “celluloepidemiology", revealing infections missed by antibodies and unique signatures linked to long COVID.
Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%.
bit.ly/498lvsu
Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%.
bit.ly/498lvsu
Case Study: How University of Antwerp differentiated COVID-19 disease severity with T Cell signatures
Discover how MiXCR + QIAGEN streamline TCR sequencing and accelerate breakthroughs in immune research
bit.ly
October 14, 2025 at 7:29 AM
New Case Study featuring MiXCR + Qiagen: University of Antwerp pioneers “celluloepidemiology", revealing infections missed by antibodies and unique signatures linked to long COVID.
Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%.
bit.ly/498lvsu
Find out how they scaled TCR profiling for population-level insights and cut prep time by 25%.
bit.ly/498lvsu